- Home
- HRZN vs NTHI Comparison
HRZN vs NTHI Comparison
Compare HRZN & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRZN | NTHI |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.1M | 243.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HRZN | NTHI |
|---|---|---|
| Price | $6.17 | $9.20 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.13 | N/A |
| AVG Volume (30 Days) | ★ 874.6K | 41.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 21.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.84 | N/A |
| Revenue Next Year | $12.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.71 | $3.20 |
| 52 Week High | $9.52 | $16.00 |
Technical Indicators
Market Signals| Indicator | HRZN | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 40.15 | 46.07 |
| Support Level | $5.71 | $8.29 |
| Resistance Level | $6.77 | $10.96 |
| Average True Range (ATR) | 0.18 | 0.78 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 40.32 | 22.77 |
Price Performance
Historical ComparisonAbout HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).